Polyvalent pneumococcal polysaccharide-protein conjugate composition
Provided is an immunogenic composition comprising 15 different polysaccharide-protein conjugates. Each of the conjugates comprises a capsular polysaccharide prepared from different serotype Streptococcus pneumoniae conjugated to a carrier protein, that is, serotypes 1, 2, 3, 4, 5, 6A, 6B, 7F, 9N, 9V, 14, 18C, 19A, 19F and 23F. An immunogenic composition formulated into a vaccine comprising an aluminum-based adjuvant increases application range with respect to pneumococcal diseases in infants and children.
1. A multivalent immunogenic composition comprising 15 distinct polysaccharide-protein conjugates, together with at least one of a physiologically acceptable vehicle and an adjuvant, wherein each of the polysaccharide-protein conjugates comprises a capsular polysaccharide from a different serotype of Streptococcus pneumoniae conjugated to a carrier protein, and the capsular polysaccharides are prepared from serotypes 1, 2, 3, 4, 5, 6A, 6B, 7F, 9N, 9V, 14, 18C, 19A, 19F and 23F and no other S. pneumoniae polysaccharide from a different serotype and wherein the carrier protein is CRM 197 , wherein the number of the polysaccharide-protein conjugates comprised in the composition does not exceed 15.
2. The multivalent immunogenic composition of claim 1 , wherein the adjuvant is an aluminum-based adjuvant.
3. The multivalent immunogenic composition of claim 2 , wherein the adjuvant is selected from the group consisting of aluminum phosphate, aluminum sulfate and aluminum hydroxide.
4. The multivalent immunogenic composition of claim 3 , wherein the adjuvant is aluminum phosphate.
5. The multivalent immunogenic composition of claim 1 , which is for inducing an immune response to a Streptococcus pneumoniae capsular polysaccharide conjugate.
6. The multivalent immunogenic composition of claim 5 , wherein the multivalent immunogenic composition is a single 0.5 ml dose formulated to contain:
2 μg of each saccharide, except for 6B at 4 μg;
approximately 34 μg of the CRM 197 carrier protein;
0.125 mg of elemental aluminum (0.5 mg aluminum phosphate) adjuvant; and
sodium chloride and sodium succinate buffer as excipients.
7. The multivalent immunogenic composition of claim 2 , which is for inducing an immune response to a Streptococcus pneumoniae capsular polysaccharide conjugate.
8. The multivalent immunogenic composition of claim 7 , wherein the multivalent immunogenic composition is a single 0.5 ml dose formulated to contain:
2 μg of each saccharide, except for 6B at 4 μg;
approximately 34 μg of the CRM 197 carrier protein;
0.125 mg of elemental aluminum (0.5 mg aluminum phosphate) adjuvant; and
sodium chloride and sodium succinate buffer as excipients.
9. The multivalent immunogenic composition of claim 3 , which is for inducing an immune response to a Streptococcus pneumoniae capsular polysaccharide conjugate.
10. The multivalent immunogenic composition of claim 9 , wherein the multivalent immunogenic composition is a single 0.5 ml dose formulated to contain:
2 μg of each saccharide, except for 6B at 4 μg;
approximately 34 μg of the CRM 197 carrier protein;
0.125 mg of elemental aluminum (0.5 mg aluminum phosphate) adjuvant; and
sodium chloride and sodium succinate buffer as excipients.
11. The multivalent immunogenic composition of claim 4 , which is for inducing an immune response to a Streptococcus pneumoniae capsular polysaccharide conjugate.
12. The multivalent immunogenic composition of claim 11 , wherein the multivalent immunogenic composition is a single 0.5 ml dose formulated to contain:
2 μg of each saccharide, except for 6B at 4 μg;
approximately 34 μg of the CRM 197 carrier protein;
0.125 mg of elemental aluminum (0.5 mg aluminum phosphate) adjuvant; and
sodium chloride and sodium succinate buffer as excipients.